Bayer's Two Clocks: A Missouri Judge Weighs $7.25 Billion While Ten Blockbusters Take Shape
Published on 09/23/2026 at 19:01 | Editorial boerse-global.de
Two very different timelines are running simultaneously at Bayer, and the market is watching both. One is measured in court dates and settlement approvals; the other stretches across a decade of drug development. For now, investors appear more focused on the first.
The Missouri Filing
Monsanto, the Bayer subsidiary at the center of the Roundup litigation, asked a Missouri state court on September 14 to approve a comprehensive settlement worth $7.25 billion. The filing represents the Leverkusen-based group's latest attempt to draw a line under years of legal exposure tied to the glyphosate-based herbicide.
Roughly 65,000 claims remain outstanding across U.S. state and federal courts, according to the company. Getting the agreement formally confirmed is seen as a prerequisite for gradually reducing the legal uncertainty that has weighed on Bayer since it acquired Monsanto in 2018.
The path is not automatic. Reuters reported that Judge Timothy Boyer was expected to review objections to the deal at the Missouri court starting September 11. A final green light from the bench would give management meaningful planning certainty on the remaining litigation complexes — and, in the eyes of the market, a key condition for a sustained re-rating of the stock.
Pipeline Ambitions Take Shape
Away from the courtroom, Bayer is pushing ahead on both of its core divisions. The centerpiece of its medium-term growth strategy is an ambition to bring ten potential blockbuster medicines to market within ten years. Two of those high-revenue candidates are already being commercialized, with further launches in preparation.
Should investors sell immediately? Or is it worth buying Bayer?
The pharmaceutical unit has logged notable regulatory wins in the U.S. of late. On September 17, the FDA approved Finerenon under the brand name Kerendia for treating adults with chronic kidney disease associated with type-1 diabetes. According to Bayer, it is the first FDA-approved therapy for this specific condition in more than three decades.
That decision followed an accelerated approval on September 9 for sevabertinib, a cancer drug cleared as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer who carry specific activating mutations. The approval covers patients with non-squamous tumors and broadens the company's oncology portfolio.
Crop Science and Renewable Fuels
On the agricultural side, Bayer is reshaping its portfolio as well. More than 15 new modes of action are in early-stage research within the Crop Science division, driven largely by CropKey, the company's in-house digital research platform designed to identify new crop-protection molecules in a targeted way.
The company is also extending its reach into alternative energy value chains. On September 9, Bayer signed a commercial agreement with Finnish group Neste to jointly expand cultivation of its proprietary newgold® winter rapeseed across the southern Great Plains of the United States. The resulting feedstock is destined for renewable diesel and sustainable aviation fuel production, opening additional sales markets for the agricultural business.
Where the Stock Stands
Market participants have taken the recent flow of news in stride. The Bayer share recently changed hands at EUR 49.28, with a gain of 33 percent since the start of the year. A separate reading put the stock at EUR 49.50, up 34 percent year-to-date — both figures reflecting the same broad recovery.
The DAX-listed stock sits 8.1 percent below its 52-week high of EUR 53.86. Whether Bayer can close that gap over the longer term will depend heavily on how quickly the new active ingredients from pharma and agriculture translate into the expected revenue contributions — and on whether a Missouri judge signs off on the $7.25 billion handshake that still hangs over the equity.
Ad
Bayer Stock: New Analysis - 23 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
